Company intelligence

MESO

Mesoblast Limited · NASDAQ · Healthcare

Price$14.99-3.17% · −$0.49

Market cap1.94BEquity value

P / E-11.8Trailing ratio

Volume25.63KLatest session

Market data

MESO price chart

TradingView

Related signals

1 min delayed

Browse public MESO signals with their source context and measured market impact. Open any signal for its permanent analysis page.

MESOAug 17, 2026+9.14% since signal

Mesoblast completes Phase 3 CLBP treatment; readout expected in 2027

Mesoblast reports completion of patient treatment in the MSB-DR004 Phase 3 trial for rexlemestrocel-L in chronic low back pain, with 350 patients treated. The RMAT designation supports potential priority FDA review, and top-line results are due mid-2027 after the 12-month follow-up. The program targets a multibillion-dollar revenue path if approved, underscoring meaningful upside for MESO investors.

View signal analysis

MESOFeb 12, 2026-8.74% since signal

Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy

The recent press release highlights Ryoncil's efficacy in patients with steroid-refractory acute graft versus host disease, showing promising survival rates. This could lead to increased demand for earlier intervention strategies in treatment, potentially benefiting MESO's market position and revenue. Investor confidence may rise as Ryoncil gains visibility for its therapeutic benefits.

View signal analysis

Research